

10th October 2023

**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001.

**The National Stock Exchange of India Limited**  
Exchange Plaza, 5<sup>th</sup> Floor  
Plot No. C/1, G. Block  
Bandra Kurla Complex,  
Bandra (East), Mumbai - 400 051.

Script Code: 500259

Script Code: LYKALABS

Dear Sir/ Madam,

**Sub.: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**Ref.: Receipt of product permission from Central Drugs Standard Control Organization of India for Tofacitinib Ointment 2% w/w.**

Pursuant to the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; we would like to inform you that, the Company has received the product permission from the Central Drugs Standard Control Organization of India to Manufacture and Market Tofacitinib Ointment 2% w/w.

The Company has received this permission after successfully completing the Clinical Trial on 125 patients across 8 Clinical Trial Centers within India.

Kindly take the above information on your record.

Thanking You,

Yours faithfully,

For Lyka Labs Limited



**Kishore P. Shah**  
Company Secretary & Compliance Officer